About InterVenn
InterVenn is a company based in San Francisco (United States) founded in 2017. InterVenn has raised $250.9 million across 6 funding rounds from investors including SoftBank Group, Genoa Ventures and Heritage Provider Network. InterVenn offers products and services including GlycoVision and Liquid Biopsy Platform. InterVenn operates in a competitive market with competitors including Miroculus, Geneoscopy, HalioDx, Magentiq Eye and AcuamarkDx, among others.
- Headquarter San Francisco, United States
-
Sectors
Healthcare
-
Email
Locked
-
Phone
Locked
-
Website
Locked
-
Social
Locked
-
Annual Revenue
Not available
-
Net Profit
Not available
-
EBITDA
Not available
-
Total Equity Funding
$250.9 M (USD)
in 6 rounds
-
Latest Funding Round
Not available
-
Investors
SoftBank Group
& 10 more
-
Employee Count
Not available
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Products & Services of InterVenn
InterVenn offers a comprehensive portfolio of products and services, including GlycoVision and Liquid Biopsy Platform.
Platform for analyzing glycoprotein structures in precision medicine.
Tool for detecting diseases through glycoproteome insights.
People of InterVenn
Unlock access to complete
Unlock access to complete
Funding Insights of InterVenn
InterVenn has successfully raised a total of $250.9M across 6 strategic funding rounds. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
Investors in InterVenn
InterVenn has secured backing from 11 investors, including venture fund and institutional investors. Prominent investors backing the company include SoftBank Group, Genoa Ventures and Heritage Provider Network.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Early-stage VC firm focused on life science startups
|
Locked | Locked | Locked | |
|
Early-stage startups are invested in by sector-agnostic VC fund.
|
Locked | Locked | Locked | |
|
Technical founders are supported through early-stage venture capital investments.
|
Locked | Locked | Locked |
Investor details for InterVenn
Investor domains, locations, round participation, and complete history require an active premium plan.
- Investor domains
- Investor locations
- Funding rounds
- Participation history
Verified entity values are shown only after access is granted.
Investments & Acquisitions by InterVenn
Investment portfolio details for InterVenn
Portfolio company identities, transaction dates, round details, and investment values require an active premium plan.
- Portfolio identities
- Transaction dates
- Round details
- Investment values
Verified entity values are shown only after access is granted.
Financial Statements - InterVenn
Detailed financials for InterVenn
Historical revenue, profit, statement rows, ratios, and trend charts require an active premium plan.
- Historical revenue
- Profit trends
- Statement rows
- Financial ratios
Verified entity values are shown only after access is granted.
Intervenn Comparisons
Peer comparison for InterVenn
Named peer metrics, headcount, funding, location, and side-by-side benchmarks require an active premium plan.
- Named peers
- Headcount comparison
- Funding comparison
- Operating benchmarks
Verified entity values are shown only after access is granted.
Competitors of InterVenn
InterVenn operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Miroculus, Geneoscopy, HalioDx, Magentiq Eye and AcuamarkDx, among others.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| Locked | Locked | Locked |
MicroRNA profiling platform is developed to detect genes in samples.
|
|
| Locked | Locked | Locked |
Non-invasive biomarker tests for colorectal cancer are developed.
|
|
| Locked | Locked | Locked |
Developer of diagnostic product for colon cancer
|
|
| Locked | Locked | Locked |
Computer vision software is utilized for endoscopic medical procedures.
|
|
| Locked | Locked | Locked |
Non-invasive screening tests for early cancer detection are provided.
|
Detailed competitors of InterVenn
Competitor domains, locations, full profiles, and operating metrics require an active premium plan.
- Domains and locations
- Full company profiles
- Operating metrics
- Competitive positioning
Verified entity values are shown only after access is granted.
Latest news on Intervenn
Complete news archive for InterVenn
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about InterVenn
InterVenn was founded in 2017 and raised its 1st funding round 1 year after it was founded.
InterVenn is headquartered in San Francisco, United States. It is registered at San Francisco, California, United States.
Andrew Quong is the current CEO of InterVenn.
InterVenn is a funded company, having raised a total of $250.9M across 6 funding rounds to date.
Provider of an AI-based clinical decision supporting tool for cancer detection and drug development. The company has developed tools like Dawn which is immune-oncology testing software that uses glycoproteomics and AI. The VISTA tool assists with the quantification of proteins in serum or blood. It has features to analyze clinical biomarkers for disease diagnosis, drug development, and treatment prediction. The VOCAL is a diagnostic tool for detecting cancer in ovaries.
InterVenn's top competitors include Geneoscopy, AcuamarkDx and Miroculus.
InterVenn offers GlycoVision and Liquid Biopsy Platform.
InterVenn has 11 investors. Key investors include SoftBank Group, Genoa Ventures, Heritage Provider Network, Irving Investors, and Amplify Partners.